The revenue of Syneos Health, Inc. with headquarters in the United States amounted to **** billion U.S. dollars in 2022. The reported fiscal year ends on December 31.Compared to the earliest depicted value from 2018 this is a total increase by approximately * billion U.S. dollars. The trend from 2018 to 2022 shows, however, that this increase did not happen continuously.

Clinical trial support service providers have experienced robust growth in recent years, driven by several key factors. Two major catalysts contributing to this growth are an increasing demand for innovative therapies and tech advances. As pharmaceutical companies race to develop new drugs and biologics to address unmet medical needs, the volume and complexity of clinical trials have surged. A jump in clinical trial activity has fueled the need for efficient and reliable solutions to handle challenging aspects of the clinical trial process, including patient recruitment and regulatory compliance. While macroeconomic headwinds have created a complex environment, this is a transient effect and not reflective of broader growth trends in the industry. In all, revenue growth has weakened, falling at a CAGR of 2.0% to an estimated $8.6 billion over the past five years, including expected growth of 2.5% in 2024. A key factor driving the rise of outsourcing in clinical research is the increasingly complex landscape of clinical trials. Advances in medicine and technology have made the trial process more intricate, leading to a greater volume and diversity of tasks, from patient recruitment to regulatory compliance. These complexities pose significant challenges that pharmaceutical and biotechnology companies are addressing through clinical trial support services. Outsourcing these services has become particularly important for smaller pharmaceutical companies that rely on successful clinical trials but lack the capital or infrastructure to manage all aspects in-house. By leveraging outsourced expertise, these companies can focus on their core activities while ensuring trials are conducted smoothly and effectively. Outsourcing components of the research and development phase is becoming an appealing strategy for downstream pharmaceutical and medical device manufacturers, setting the stage for the industry’s growth. Smaller and mid-sized pharmaceutical firms will vie with major multinational companies to introduce innovative therapies, strengthening the industry’s role. Additionally, a looming patent cliff will spur demand for outsourced clinical trial services as revenue drops and heightened competition from generic drugs prompt these manufacturers to boost clinical trial activities and implement cost-saving measures. Revenue will continue growing, rising at a CAGR of 3.1% over the next five years, reaching an estimated $9.9 billion in 2029.

The global Pharmaceutical Contract Sales Organization (CSO) market is booming, projected to reach $7.9B in 2025 with a 5.3% CAGR. Learn about key drivers, trends, and regional market shares in this comprehensive analysis. Explore top companies and future growth opportunities in the pharmaceutical outsourcing sector.

The global Pharmaceutical Contract Sales Organization (CSO) market is experiencing robust growth, driven by increasing outsourcing trends within the pharmaceutical industry. Pharmaceutical companies are increasingly leveraging CSOs to access specialized sales expertise, expand market reach, and optimize sales force efficiency, particularly for niche products or in geographically challenging markets. This strategic shift is further fueled by the rising complexity of regulatory landscapes and the need for efficient, data-driven sales strategies. The market's expansion is also influenced by the growing adoption of digital sales channels and the increasing demand for specialized sales forces capable of effectively targeting key opinion leaders and healthcare professionals. We estimate the market size to be approximately $15 billion in 2025, with a Compound Annual Growth Rate (CAGR) of 7% projected through 2033. This growth trajectory is expected to be underpinned by continued pharmaceutical innovation, the emergence of new therapeutic areas, and the ongoing need for cost-effective sales solutions. The competitive landscape is characterized by a mix of global players and regional specialists. Established players like IQVIA, Syneos Health, and Phoenix Group hold significant market share, benefiting from their extensive networks and established operational capabilities. However, the market also presents opportunities for smaller, specialized CSOs focusing on niche therapeutic areas or specific geographic regions. The ongoing consolidation within the pharmaceutical industry is also expected to further drive demand for CSO services, as companies seek to streamline operations and focus on core competencies. Challenges for the industry include maintaining data security and compliance with evolving regulations, alongside the need for continuous adaptation to new technologies and evolving sales strategies. The continued focus on delivering measurable ROI for clients will be a key determinant of success in this dynamic market.

Discover the booming Pharmaceutical Contract Sales Outsourcing (CSO) market! Explore its $25 billion (2025 est.) size, 5% CAGR, key drivers, regional trends, and top players. Learn about growth opportunities in oncology, cardiovascular, and other therapeutic areas.

Report Attribute/Metric	Details
Market Size 2024	8.5 billion USD
Market Size in 2025	USD 9.3 billion
Market Size 2030	14.3 billion USD
Report Coverage	Market Size for past 5 years and forecast for future 10 years, Competitive Analysis & Company Market Share, Strategic Insights & trends
Segments Covered	Offered Services, End-user, Phase, Company Size, Medical Device
Regional Scope	North America, Europe, Asia Pacific, Latin America and Middle East & Africa
Country Scope	U.S., Canada, Mexico, UK, Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Mexico, Argentina, Saudi Arabia, UAE and South Africa
Top 5 Major Countries and Expected CAGR Forecast	U.S., Germany, UK, France, China - Expected CAGR 6.6% - 9.6% (2025 - 2034)
Top 3 Emerging Countries and Expected Forecast	India, Brazil, Mexico - Expected Forecast CAGR 8.7% - 11.4% (2025 - 2034)
Companies Profiled	IQVIA Inc., Charles River Laboratories, ICON plc, Syneos Health, WuXi AppTec, Medpace, Eurofins Scientific SE, Promedica International, Qserve and Avania

Introduction

Global Preclinical CRO Market size is expected to be worth around US$ 10.5 Billion by 2032 from US$ 5.2 Billion in 2023, growing at a CAGR of 7.5% during the forecast period from 2023 to 2032. In 2022, North America led the market, achieving over 47.50% share with a revenue of US$ 2.47 Billion.

This market's expansion is largely fueled by heightened investments in drug discovery and the increased inclination towards outsourcing preclinical studies to CROs that provide specialized services such as bioanalysis, toxicology testing, and drug metabolism and pharmacokinetic (DMPK) studies.

Driving factors for the preclinical CRO market include the rising prevalence of chronic diseases, which necessitates new pharmaceuticals, thus enhancing the demand for preclinical research. North America leads in market share due to its advanced healthcare infrastructure and the presence of major pharmaceutical firms investing in R&D. Conversely, the Asia Pacific is poised for rapid growth, driven by cost efficiencies and a regulatory environment conducive to outsourcing preclinical studies.

Challenges such as stringent regulatory standards imposed by bodies like the U.S. FDA and the European Medicines Agency (EMA) could impede market growth by complicating the drug approval processes.

Parexel International Corporation, a prominent clinical research organization, has significantly bolstered its market position through acquisitions, strategic alliances, and technology advancements. In July 2021, EQT Private Equity and Goldman Sachs Asset Management acquired Parexel for $8.5 billion, aiming to expand its global footprint and enhance services like decentralized clinical trials and data management.

https://sp-ao.shortpixel.ai/client/to_auto,q_lossy,ret_img,w_1216,h_734/https://market.us/wp-content/uploads/2023/08/Global-Preclinical-CRO-Markett.jpg" alt="Preclinical CRO Market Size" class="wp-image-104629">

In August 2023, Parexel entered a strategic alliance with Partex, leveraging artificial intelligence (AI) and big data to improve biopharmaceutical clients’ project success rates by discovering new potential disease applications for their assets.

Additionally, in January 2024, Parexel partnered with the Japanese Foundation for Cancer Research to enhance access to oncology clinical trials in Japan, increasing the efficiency of clinical research and expanding patient treatment options.

The sector continues to experience significant global consolidation, as evidenced by FHI Clinical’s acquisition of Triclinium Clinical Development’s operations in South Africa and the purchase of Syneos Health by a consortium including Elliott Investment Management, Patient Square Capital, and Veritas Capital for around $7.1 billion. These mergers and acquisitions aim to enhance service capabilities and broaden geographic coverage.

The global Clinical Trials market is valued at USD 126.4 billion in 2025 and is projected to reach USD 192.6 billion by 2035, growing at a steady 4.3% CAGR.

Metric	Value
Industry Size (2025E)	USD 126.4 billion
Industry Value (2035F)	USD 192.6 billion
CAGR (2025 to 2035)	4.3%

Clinical Trials Market Analysis by Top Investment Segments

Phase Segment	CAGR (2025 to 2035)
Phase 4	5%

Clinical Trials Market Analysis by Top Countries

Country	CAGR (2025 to 2035)
United States	5%

Country	CAGR (2025 to 2035)
China	5.8%

Country	CAGR (2025 to 2035)
Japan	3.2%

Country	CAGR (2025 to 2035)
Germany	5.6%

Country	CAGR (2025 to 2035)
United Kingdom	4.7%

Country	CAGR (2025 to 2035)
France	4.3%

Country	CAGR (2025 to 2035)
Spain	3.8%

Country	CAGR (2025 to 2035)
Canada	3.9%

Country	CAGR (2025 to 2035)
South Korea	4.5%

Country	CAGR (2025 to 2035)
India	6.1%

Clinical Trials Market Players Strategies and Share Analysis

Company Name	Estimated Market Share (%)
IQVIA	14-16%
ICON plc	10-12%
Charles River Laboratories	9-11%
Pharmaceutical Product Development (PPD)	8-10%
Syneos Health	7-9%

Report Attribute/Metric	Details
Market Size 2024	9.6 billion USD
Market Size in 2025	USD 10.8 billion
Market Size 2030	19.1 billion USD
Report Coverage	Market Size for past 5 years and forecast for future 10 years, Competitive Analysis & Company Market Share, Strategic Insights & trends
Segments Covered	Phase, Application/Indication, Design
Regional Scope	North America, Europe, Asia Pacific, Latin America and Middle East & Africa
Country Scope	U.S., Canada, Mexico, UK, Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Mexico, Argentina, Saudi Arabia, UAE and South Africa
Top 5 Major Countries and Expected CAGR Forecast	U.S., Germany, UK, Japan, China - Expected CAGR 10.9% - 14.5% (2025 - 2034)
Top 3 Emerging Countries and Expected Forecast	Brazil, India, South Africa - Expected Forecast CAGR 8.5% - 12.7% (2025 - 2034)
Companies Profiled	MEDPACE, Novartis, Exscientia, Syneos Health, AstraZeneca, IQ BIOTECH, BioNTech, IQVIA Holdings, ICON Plc, Covance and Inc.

The global Pharmaceutical Contract Sales Outsourcing (CSO) market is booming, projected to reach $15 billion in 2025 with a 5% CAGR. Learn about key drivers, trends, restraints, and top players in this dynamic industry. Explore regional market shares and growth forecasts for informed business decisions.

Report Attribute/Metric	Details
Market Size 2024	53.9 billion USD
Market Size in 2025	USD 57.3 billion
Market Size 2030	77.7 billion USD
Report Coverage	Market Size for past 5 years and forecast for future 10 years, Competitive Analysis & Company Market Share, Strategic Insights & trends
Segments Covered	Service Type, End-user, Therapeutic Area/Domain
Regional Scope	North America, Europe, Asia Pacific, Latin America and Middle East & Africa
Country Scope	U.S., Canada, Mexico, UK, Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Mexico, Argentina, Saudi Arabia, UAE and South Africa
Top 5 Major Countries and Expected CAGR Forecast	U.S., Germany, UK, France, Japan - Expected CAGR 4.1% - 6.0% (2025 - 2034)
Top 3 Emerging Countries and Expected Forecast	China, India, Brazil - Expected Forecast CAGR 7.2% - 8.7% (2025 - 2034)
Companies Profiled	The Quantic Group, IQVIA, Parexel International Corporation, Lachman Consultant Services Inc., GMP Pharmaceuticals Pty Ltd., Concept Heidelberg GmbH, LabCorp, Charles River Laboratories, ICON plc, Syneos Health, Lonza and Catalent Inc.

The central lab market is projected to grow at a CAGR of 5.6%, increasing from USD 3,012.8 Million in 2025 to approximately USD 5,195.3 Million by 2035.

Metric	Value
Market Size in 2025	USD 3,012.8 Million
Projected Market Size in 2035	USD 5,195.3 Million
CAGR (2025 to 2035)	5.6%

Country-Wise Outlook

Country	CAGR (2025 to 2035)
United States	5.9%

Country	CAGR (2025 to 2035)
United Kingdom	5.4%

Country	CAGR (2025 to 2035)
European Union	5.6%

Country	CAGR (2025 to 2035)
Japan	5.3%

Country	CAGR (2025 to 2035)
South Korea	5.8%

Segmentation Outlook - Central Lab Market

Service Type	Market Share (2025)
Biomarker Services	68.5%

End User	Market Share (2025)
Pharmaceutical Companies	66.2%

Competitive Outlook

Company Name	Estimated Market Share (%)
Labcorp Drug Development	14-17%
Eurofins Scientific SE	11-14%
ICON plc	9-12%
PPD (Thermo Fisher Scientific)	7-10%
Syneos Health	6-9%
Other Providers	38-45%

BASE YEAR	2024
HISTORICAL DATA	2019 - 2023
REGIONS COVERED	North America, Europe, APAC, South America, MEA
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
MARKET SIZE 2024	10.3(USD Billion)
MARKET SIZE 2025	10.9(USD Billion)
MARKET SIZE 2035	18.5(USD Billion)
SEGMENTS COVERED	Service Type, Therapeutic Area, End User, Engagement Model, Regional
COUNTRIES COVERED	US, Canada, Germany, UK, France, Russia, Italy, Spain, Rest of Europe, China, India, Japan, South Korea, Malaysia, Thailand, Indonesia, Rest of APAC, Brazil, Mexico, Argentina, Rest of South America, GCC, South Africa, Rest of MEA
KEY MARKET DYNAMICS	growing biotechnology sector, increasing healthcare expenditure, demand for specialized sales expertise, shift towards outsourcing, rising competition in pharmaceuticals
MARKET FORECAST UNITS	USD Billion
KEY COMPANIES PROFILED	PAREXEL International, IQVIA, Ventiv Health, InVentiv Health, Catalent, Apexity, PPD, Eisai, Medpace, Covance, Celerion, LSG Sky Chefs, Bioclinica, Syneos Health, Daiichi Sankyo
MARKET FORECAST PERIOD	2025 - 2035
KEY MARKET OPPORTUNITIES	Increased demand for specialized salesforces, Growth of biopharmaceuticals outsourcing, Technological advancements in sales analytics, Expansion in emerging markets, Shift towards performance-based contracts
COMPOUND ANNUAL GROWTH RATE (CAGR)	5.5% (2025 - 2035)

Report Attribute/Metric	Details
Market Size 2024	784 million USD
Market Size in 2025	USD 854 million
Market Size 2030	1.31 billion USD
Report Coverage	Market Size for past 5 years and forecast for future 10 years, Competitive Analysis & Company Market Share, Strategic Insights & trends
Segments Covered	Product Formulation, Therapeutic Application, Health Care Setting, Patient Demography, Reimbursement Scenario
Regional Scope	North America, Europe, Asia Pacific, Latin America and Middle East & Africa
Country Scope	U.S., Canada, Mexico, UK, Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Mexico, Argentina, Saudi Arabia, UAE and South Africa
Top 5 Major Countries and Expected CAGR Forecast	U.S., Germany, France, Japan, UK - Expected CAGR 6.6% - 9.5% (2025 - 2034)
Top 3 Emerging Countries and Expected Forecast	Thailand, UAE, Chile - Expected Forecast CAGR 8.6% - 11.3% (2025 - 2034)
Companies Profiled	Sanofi, Regeneron Pharmaceuticals, Open Orphan, Syneos Health, TFS International, GenScript, Covance, Pharmaceutical Product Development LLC, ICON plc, IQVIA, WuXi AppTec and PRA Health Sciences

BASE YEAR	2024
HISTORICAL DATA	2019 - 2023
REGIONS COVERED	North America, Europe, APAC, South America, MEA
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
MARKET SIZE 2024	51.5(USD Billion)
MARKET SIZE 2025	53.5(USD Billion)
MARKET SIZE 2035	78.0(USD Billion)
SEGMENTS COVERED	Service Type, Therapeutic Area, Study Phase, End User, Regional
COUNTRIES COVERED	US, Canada, Germany, UK, France, Russia, Italy, Spain, Rest of Europe, China, India, Japan, South Korea, Malaysia, Thailand, Indonesia, Rest of APAC, Brazil, Mexico, Argentina, Rest of South America, GCC, South Africa, Rest of MEA
KEY MARKET DYNAMICS	Growing demand for outsourcing, Increasing R&D cost pressures, Advancements in biopharmaceuticals, Regulatory compliance complexities, Rising focus on patient-centric studies
MARKET FORECAST UNITS	USD Billion
KEY COMPANIES PROFILED	Eurofins Scientific, PPD, IQVIA, AptarGroup, Parexel, Medpace, Recipharm, Labcorp Drug Development, Charles River Laboratories, William Green, Catalent, Syneos Health, Celerion, Albany Molecular Research, Frontage Laboratories, Inc.
MARKET FORECAST PERIOD	2025 - 2035
KEY MARKET OPPORTUNITIES	Increased demand for outsourcing, Growth in biopharmaceuticals, Advancements in technology integration, Expansion into emerging markets, Focus on personalized medicine
COMPOUND ANNUAL GROWTH RATE (CAGR)	3.9% (2025 - 2035)

BASE YEAR	2024
HISTORICAL DATA	2019 - 2023
REGIONS COVERED	North America, Europe, APAC, South America, MEA
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
MARKET SIZE 2024	6.6(USD Billion)
MARKET SIZE 2025	6.9(USD Billion)
MARKET SIZE 2035	12.0(USD Billion)
SEGMENTS COVERED	Type of Material, Phase of Clinical Trials, Therapeutic Area, Distribution Channel, Regional
COUNTRIES COVERED	US, Canada, Germany, UK, France, Russia, Italy, Spain, Rest of Europe, China, India, Japan, South Korea, Malaysia, Thailand, Indonesia, Rest of APAC, Brazil, Mexico, Argentina, Rest of South America, GCC, South Africa, Rest of MEA
KEY MARKET DYNAMICS	rising demand for personalized medicine, increasing investment in R&D, stringent regulatory requirements, growing prevalence of chronic diseases, advancements in clinical trial technology
MARKET FORECAST UNITS	USD Billion
KEY COMPANIES PROFILED	ICON, Bluebird Bio, Lambda Therapeutic Research, PPD, PAREXEL, Medpace, Covance, WuXi AppTec, Celerion, KCR, Eurofins Scientific, Charles River Laboratories, BioClinica, Worldwide Clinical Trials, Syneos Health, Quintiles
MARKET FORECAST PERIOD	2025 - 2035
KEY MARKET OPPORTUNITIES	Increased demand for personalized medicine, Rising investment in biopharmaceutical research, Growing outsourcing of clinical trials, Expansion of generics and biosimilars market, Technological advancements in manufacturing processes
COMPOUND ANNUAL GROWTH RATE (CAGR)	5.6% (2025 - 2035)

BASE YEAR	2024
HISTORICAL DATA	2019 - 2023
REGIONS COVERED	North America, Europe, APAC, South America, MEA
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
MARKET SIZE 2024	5.85(USD Billion)
MARKET SIZE 2025	6.37(USD Billion)
MARKET SIZE 2035	15.0(USD Billion)
SEGMENTS COVERED	Type of Analytics, Application, Deployment Mode, End User, Regional
COUNTRIES COVERED	US, Canada, Germany, UK, France, Russia, Italy, Spain, Rest of Europe, China, India, Japan, South Korea, Malaysia, Thailand, Indonesia, Rest of APAC, Brazil, Mexico, Argentina, Rest of South America, GCC, South Africa, Rest of MEA
KEY MARKET DYNAMICS	Data-driven decision making, Increasing regulatory compliance, Rising R&D expenditure, Growing availability of advanced analytics tools, Integration of AI and machine learning
MARKET FORECAST UNITS	USD Billion
KEY COMPANIES PROFILED	Bain & Company, Accenture, Deloitte, Parexel International, Health Catalyst, Syneos Health, Veradigm, Optum, TCS, IMS Health, IBM Watson Health, IQVIA, Cognizant, PwC, McKinsey & Company
MARKET FORECAST PERIOD	2025 - 2035
KEY MARKET OPPORTUNITIES	Increased demand for data-driven decisions, Growth in personalized medicine analytics, Rise in regulatory compliance needs, Expansion of cloud-based analytics solutions, Integration of AI and machine learning tools
COMPOUND ANNUAL GROWTH RATE (CAGR)	9.0% (2025 - 2035)

BASE YEAR	2024
HISTORICAL DATA	2019 - 2024
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
MARKET SIZE 2023	199.16(USD Billion)
MARKET SIZE 2024	208.28(USD Billion)
MARKET SIZE 2032	298.2(USD Billion)
SEGMENTS COVERED	Service Type, End User, Function, Process, Regional
COUNTRIES COVERED	North America, Europe, APAC, South America, MEA
KEY MARKET DYNAMICS	Cost efficiency, Regulatory compliance, Technological advancements, Increasing outsourcing trends, Focus on core competencies
MARKET FORECAST UNITS	USD Billion
KEY COMPANIES PROFILED	Charles River Laboratories, Tata Consultancy Services, Infosys, QuintilesIMS, IQVIA, PPD, Cognizant, Genpact, Parexel, Maxim Healthcare Services, Wipro, Covance, Accenture, Syneos Health, LabCorp
MARKET FORECAST PERIOD	2025 - 2032
KEY MARKET OPPORTUNITIES	Rise in R&D outsourcing, Increased regulatory compliance needs, Growth of personalized medicine, Expansion in emerging markets, Advancements in technology integration
COMPOUND ANNUAL GROWTH RATE (CAGR)	4.58% (2025 - 2032)